Slow-release L-cysteine capsule prevents gastric mucosa exposure to carcinogenic acetaldehyde : results of a randomised single-blinded, cross-over study of Helicobacter-associated atrophic gastritis by Hellström, Per M. et al.
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=igas20
Scandinavian Journal of Gastroenterology
ISSN: 0036-5521 (Print) 1502-7708 (Online) Journal homepage: http://www.tandfonline.com/loi/igas20
Slow-release L-cysteine capsule prevents gastric
mucosa exposure to carcinogenic acetaldehyde:
results of a randomised single-blinded, cross-over
study of Helicobacter-associated atrophic gastritis
Per M. Hellström, Panu Hendolin, Pertti Kaihovaara, Leif Kronberg, Axel
Meierjohann, Anders Millerhovf, Lea Paloheimo, Heidi Sundelin, Kari
Syrjänen, Dominic-Luc Webb & Mikko Salaspuro
To cite this article: Per M. Hellström, Panu Hendolin, Pertti Kaihovaara, Leif Kronberg, Axel
Meierjohann, Anders Millerhovf, Lea Paloheimo, Heidi Sundelin, Kari Syrjänen, Dominic-Luc
Webb & Mikko Salaspuro (2017) Slow-release L-cysteine capsule prevents gastric mucosa
exposure to carcinogenic acetaldehyde: results of a randomised single-blinded, cross-over study
of Helicobacter-associated atrophic gastritis, Scandinavian Journal of Gastroenterology, 52:2,
230-237, DOI: 10.1080/00365521.2016.1249403
To link to this article:  https://doi.org/10.1080/00365521.2016.1249403
© 2016 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group
Published online: 03 Nov 2016.
Submit your article to this journal Article views: 867
View related articles View Crossmark data
Citing articles: 2 View citing articles 
ORIGINAL ARTICLE
Slow-release L-cysteine capsule prevents gastric mucosa exposure to
carcinogenic acetaldehyde: results of a randomised single-blinded, cross-over
study of Helicobacter-associated atrophic gastritis
Per M. Hellstr€oma, Panu Hendolinb, Pertti Kaihovaarab,c, Leif Kronbergd, Axel Meierjohannd, Anders Millerhovfe,
Lea Paloheimob, Heidi Sundelind, Kari Syrj€anenb, Dominic-Luc Webba and Mikko Salaspuroc
aDepartment of Medical Sciences, Gastroenterology and Hepatology Unit, Uppsala University Hospital, Uppsala University, Uppsala, Sweden;
bClinical Sciences, Biohit Oyj, Helsinki, Finland; cResearch Unit on Acetaldehyde and Cancer, University of Helsinki, Helsinki, Finland;
dLaboratory of Organic Chemistry, Johan Gadolin Process Chemistry Centre, Åbo Akademi University, Turku, Finland; eClinical Trial
Consultants, Uppsala University Hospital, Uppsala, Sweden
ABSTRACT
Introduction: Helicobacter-induced atrophic gastritis with a hypochlorhydric milieu is a risk factor for
gastric cancer. Microbes colonising acid-free stomach oxidise ethanol to acetaldehyde, a recognised
group 1 carcinogen.
Objective: To assess gastric production of acetaldehyde and its inert condensation product, non-toxic
2-methyl-1,3-thiazolidine-4-carboxylic acid (MTCA), after alcohol intake under treatment with slow-
release L-cysteine or placebo.
Methods: Seven patients with biopsy-confirmed atrophic gastritis, low serum pepsinogen and high
gastrin-17 were studied in a cross-over single-blinded design. On separate days, patients randomly
received 200mg slow-release L-cysteine or placebo with intragastric instillation of 15% (0.3g/kg) etha-
nol. After intake, gastric concentrations of ethanol, acetaldehyde, L-cysteine and MTCA were analysed.
Results: Administration of L-cysteine increased MTCA (p< .0004) and decreased gastric acetaldehyde
concentrations by 68% (p< .0001). The peak L-cysteine level was 7552±2687lmol/L at 40min and
peak MTCA level 196 ±98lmol/L at 80min after intake. Gastric L-cysteine and MTCA concentrations
were maintained for 3 h. The AUC for MTCA was 11-fold higher than acetaldehyde, indicating gastric
first-pass metabolism of ethanol. With placebo, acetaldehyde remained elevated also at low ethanol
concentrations representing ‘non-alcoholic’ beverages and food items.
Conclusions: After gastric ethanol instillation, slow-release L-cysteine eliminates acetaldehyde to form
inactive MTCA, which remains in gastric juice for up to 3h. High acetaldehyde levels indicate a marked gas-
tric first-pass metabolism of ethanol resulting in gastric accumulation of carcinogenic acetaldehyde. Local
exposure of the gastric mucosa to acetaldehyde can be mitigated by slow-release L-cysteine capsules.
ARTICLE HISTORY
Received 29 August 2016
Accepted 11 October 2016
KEYWORDS
Alcohol; carcinogenesis;
ethanol; prophylaxis;
stomach
Introduction
There is strong evidence supporting the crucial role of acetal-
dehyde in gastric carcinogenesis. In a meta-analysis including
total of 34 557 gastric cancer cases derived from 44 case con-
trol and 15 cohort studies, heavy drinking (more or equal to
four drinks per day) was significantly associated with increased
risk for stomach cancer.[1] In other studies, the highest risk has
been demonstrated in ALDH2-deficient alcohol consumers and
especially among those with chronic atrophic gastritis.[2,3]
Moreover, ALDH2 deficiency combined with atrophic gastritis
has been shown to increase also the risk for oesophageal squa-
mous cell carcinoma.[4] Recently, it was demonstrated that
ALDH2 deficiency results in a more than 5-fold increased
exposure of the gastric mucosa to acetaldehyde after intragas-
tric administration of a moderate dose of ethanol.[5] A recent
study of interactions between alcohol, ALDH2 and risk for
gastric cancer has also confirmed an increased risk with low
ALDH2 and high alcohol consumption.[6] When combined
with results from epidemiological studies, these findings pro-
vide concrete evidence for a causal relationship of acetalde-
hyde not only with the pathogenesis of oesophageal but also
with gastric cancer. ALDH2 deficiency has been calculated to
affect at least 540 million individuals of Eastern Asian des-
cent.[7] Thus, local carcinogenicity of acetaldehyde in the
human upper digestive tract is a world-wide observable fact.
Many microbes colonising the acid-free or hypochlorhydric
stomach possess alcohol dehydrogenase activity and are able
to locally produce acetaldehyde not only from ethanol but also
from glucose.[8] In addition to atrophic gastritis, Helicobacter
pylori infection is also a major risk factor for gastric cancer.[9]
Many H. pylori strains possess alcohol dehydrogenase and are
able to enzymatically oxidise ethanol into carcinogenic
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acetaldehyde.[10] Intragastric acetaldehyde production from
ethanol mediated by microbes is supplemented by gastric
mucosal alcohol dehydrogenase.[11,12] The limited capacity of
mucosal cells and microbes to eliminate acetaldehyde results
in accumulation of acetaldehyde in gastric contents of achlo-
rhydric patients.[5,8]
L-cysteine neutralises acetaldehyde carcinogenicity by form-
ing direct covalent bond. The product of this binding is the
non-toxic 2-methyl-1,3-thiazolidine-4-carboxylic acid
(MTCA).[13] Preparations that slowly release L-cysteine locally
in the oral cavity have been shown to successfully eliminate
acetaldehyde from the saliva during alcohol consumption and
smoking.[14,15] Our recent study shows that slow-release L-
cysteine capsules effectively eliminate ethanol-derived acetal-
dehyde also from the gastric juice of patients with atrophic
gastritis and the effect persisted at least for 40min.[16] In that
study, patients orally ingested 15% alcohol solution in a total
dose of 0.3 g/kg. The effect of L-cysteine capsules (4 50mg)
was documented to last for at least for 40min. To date, forma-
tion of MTCA from L-cysteine and acetaldehyde has not been
documented in vivo. As primary end-point, after gastric instilla-
tion of alcohol in patients with achlorhydric atrophic gastritis,
we examined the intragastric levels of acetaldehyde with or
without concomitant administration of slow-release L-cysteine.
As secondary end-point, intragastric levels of the resulting end-
products L-cysteine and MTCA were analysed.
Materials and methods
The investigation was carried out at Uppsala University
Hospital between June 2013 and May 2014 as an exploratory
single-blinded cross-over study in seven H. pylori-
positive patients, derived from a cohort of 27 patients with
biopsy-confirmed atrophic gastritis who showed low
fasting serum levels of GastroPanel tests (Biohit Oyj, Helsinki,
Finland): pepsinogen (PG) 1< 30 lg/L, PG II <3 lg/L, PGI/PGII
<3 and high fasting serum gastrin-17> 10 pmol/L partici-
pated in the study (Figure 1). Supplementation treatment
with cobalamin was received by all subjects. None had on-
going treatment with either acid inhibitory pharmaceuticals
(proton pump inhibitors, PPIs; H2-receptor blockers), antide-
pressants or non-steroid anti-inflammatory drugs. Patients
with previous or on-going alcohol or drug abuse were
excluded, as were patients on gastroprokinetics or with symp-
toms of gastroparesis. None of the patients had symptoms of
any gastrointestinal perturbation, constipation or diarrhoea.
All subjects completed this randomised cross-over study
serving as their own controls. On two separate
occasions with an interval of one week, each patient
received 15% ethanol (0.3 g/kg) by gastric instillation, ran-
domly assigned to treatment with 200-mg slow-release L-
cysteine (Acetium, Biohit Oyj, Helsinki, Finland) or placebo in
a patient-blinded fashion. Randomisation was done by enve-
lope draw by research coordinating nurse.
The study (project 620070-SWE-2012) was conducted
in accordance with the Helsinki Declaration, and
approved by the Ethics Committee for Human
Research at the Regional Investigational Review Board,
Uppsala, Sweden (diary no. 2012/411). All subjects pro-
vided written informed consent prior to enrolment in
the study. The study was registered at www.ClinicalTrials.
gov no. NCT02524262.
Figure 1. Study flow chart for subjects receiving either ethanol with L-cysteine (left) or ethanol without L-cysteine (right).
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Nasogastric intubation and gastric aspiration
All subjects were instructed to refrain from consuming alco-
hol for 24 h and food for 12 h prior to each study session,
conducted 8–11 am at the Clinical Trial Consultants research
unit. After local anaesthesia of the nasal cavity with lidocaine
gel (Xylocain 20mg/mL, AstraZeneca, S€odert€alje, Sweden;
without ethanol), a nasogastric tube was inserted through a
nostril to a depth of 55 cm with 100mL of water to facilitate
positioning. The position of the tube was confirmed by aspir-
ation of gastric contents. Immediately before administration
of 15% ethanol through the nasogastric tube, the volunteers
swallowed two slow-release L-cysteine capsules (Acetium;
Biohit Oyj, Helsinki, Finland; in total 200mg), or identical-
appearing placebo capsules, with 50mL of water. During the
session, patients were in supine position on their left side to
delay gastric emptying and facilitate the collection of adequate
gastric juice samples. Gastric aspirates (5mL) were collected at
20-min intervals for up to 240min.
Acetaldehyde, ethanol, L-cysteine and MTCA analyses of
gastric juice samples
For ethanol and acetaldehyde analysis, 5mL of gastric juice
was collected at each time point into cryo tubes containing
10% of 6mol/L perchloric acid. This is known to be sufficient to
stop microbial acetaldehyde production without hydrolysing L-
cysteine-acetaldehyde binding.[16] Then, samples were imme-
diately deep frozen and stored at 80 C until transfer on dry
ice to the Biohit laboratory for further analyses. Ethanol and
acetaldehyde concentrations were analysed by headspace gas
chromatography as duplicates, as previously described.[16,17]
For L-cysteine and MTCA analyses, 1mL of gastric juice was
immediately deep frozen and stored at 80 C until transfer on
dry ice to the Laboratory of Organic Chemistry, Åbo Akademi
University (Turku, Finland) for analyses. The determination of
L-cysteine and MTCA was performed by liquid chromatog-
raphy – mass spectrometry (LC-MS/MS) with a Micromass
Quattro Micro triple-quadrupole mass analyser (QqQ-MS)
equipped with an electrospray ion source (Waters, Milford,
MA). The mass analyser was operated in multiple reaction
monitoring mode (MRM). Positive ions were recorded. Nitrogen
was used as desolvation gas at 325 C, and the flow rate was
set to 640L per hour. Argon was used as the collision gas with
a collision cell pressure of 5.63 103 mbar. The source tem-
perature was 120 C, and the capillary voltage was set to 3.4 kV.
The mass spectrometer was coupled to an Agilent 1100 series
HPLC consisting of a binary pump, a vacuum degasser, an auto-
sampler and a thermostatted column oven (30 C).
An Atlantis T3 analytical column (3 lm, 2.1 100mm;
Waters, Ireland) equipped with a guard column of the same
material (3lm, 2.1 10mm) was used. The mobile phase
consisted of 0.5% aqueous acetic acid. The flow rate was
0.3mL per minute. The run time was 4min.
Prior to determination of L-cysteine and MTCA, samples
were thawed and diluted 1:10 with a solution containing 4%
formic acid, 0.25mg/mL dithiothreitol and 1 lg/mL cysteine-
D3 as internal standard in water. All samples were analysed
in triplicate. The injected volume was 10 lL.
Two transitions (122> 86.9; 122> 76.1 and 148.1> 130.8;
148.1> 102.2 mass units) were monitored for L-cysteine and
MTCA, respectively. Quantification was performed using a 6-point
linear calibration curve with R2 > .98.
Calibration curves ranging between 0.1–40lg/mL for MTCA
and 0.5–200lg/mL for L-cysteine were used. The repeatability
was calculated as the relative SD from 10 injections and was
7.3% for L-cysteine and 5.6% for MTCA, for the concentrations
of 50lg/mL and 10lg/mL, respectively. The matrix effect was
determined by calculating the difference in peak area in Milli-
QVR water compared to the peak area for the same concentra-
tion in matrix (five injections each). Due to the strong matrix
effect for MTCA, a correction factor of 0.24 was used. The limit
of quantification (LOQ) of L-cysteine and MTCA in the samples
was defined as the concentration having signal-to-noise ratio
(S/N) value of 10 and limit of detection (LOD) an S/N value
of 3. The detection limit for the instrument was 1ng/mL
(8nmol/L equivalent to 10pg on column) for L-cysteine and
15ng/mL (102nmol/L equivalent to 151pg on column) for
MTCA.
L-cysteine slow-release capsules (acetium)
Each capsule (Acetium, Biohit Oyj, Helsinki, Finland) contains
100-mg L-cysteine in slow-release formulation as the active
ingredient. L-cysteine is bound with matrix granules including
EudragitVR RS-PO, hypromellose, calcium hydrogen phosphate
and titanium dioxide. In dissolution tests, this formulation has
been shown to release L-cysteine at a controlled rate, which is
sufficiently fast permit time to react with acetaldehyde before
the formulation leaves the stomach.[16] A placebo formulation
where L-cysteine was replaced with the same amount of
CaHPO4 was prepared following exactly the same method.
Statistical analysis
Concentrations of ethanol, acetaldehyde, L-cysteine and
MTCA were expressed as means ± SEM. Exposures of the gas-
tric mucosa were expressed as the area under the curve
(AUC) of acetaldehyde and MTCA, respectively. Statistical
differences between the slow-release L-cysteine and pla-
cebo groups were analysed using the paired Student’s
t-test; p< .05 was considered statistically significant. All
statistical analyses were exploratory and conducted using
GraphPad Prism, version 6.03 (GraphPad Software Inc.,
La Jolla, CA).
Results
All the seven subjects completed the study serving as
their own controls. No significant unintended adverse reac-
tions were encountered, albeit some slight tipsiness
occurred.
Ethanol in gastric juice
After intragastric instillation of 15 vol% alcohol (ethanol
0.3 g/kg), the peak ethanol concentration in gastric juice at
10min reached 5.8 ± 0.8 vol% with placebo and 6.1 ± 0.9
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vol% with L-cysteine (Figure 1). Thereafter, ethanol levels of
gastric contents declined in parallel to 0.03 ± 0.003 vol% in
placebo and to 0.06 ± 0.03 vol% in L-cysteine groups at
120min, respectively (Figure 2). These levels correspond to
6.3–12.6mmol/L ethanol, which is still more than enough for
significant local acetaldehyde production.[17] No significant
differences were found in gastric juice ethanol exposure in
the placebo or L-cysteine setting. At 40min, the mean gastric
juice ethanol levels were 2.96 ± 0.66 vol% in placebo and
2.69 ± 0.52 vol% in L-cysteine groups. These values are close
to the official ethanol limit (2.8 vol%) for alcoholic beverages
in Finland.
Effect of slow-release L-cysteine on gastric juice
acetaldehyde
In placebo experiments, peak acetaldehyde concentration in
gastric juice (43.9 ± 8.8 lmol/L) was achieved at 40min after
intragastric alcohol infusion (Figure 2(A)). At 60min, the acetal-
dehyde level was still markedly increased at 39.9 ±10.5lmol/L,
thereafter levelling off to 9.6±1.8lmol/L at 120min.
After treatment with slow-release L-cysteine capsules in
addition to ethanol, the gastric acetaldehyde concentration
was significantly reduced to 13.3±2.7lmol/L occurring
already 20min after intake, as compared to placebo with
39.9±7.6lmol/L (p¼ 0.0063). The peak acetaldehyde concentra-
tion of 43.9±8.76lmol/L at 40min with placebo was markedly
reduced with the addition of L-cysteine to 6.32±1.80lmol/L
(p¼ .0008). The effect of L-cysteine was maintained over
120min (Figure 3(A)). As estimated by the AUC, over the whole
study period, slow-release L-cysteine reduced the gastric expos-
ure of acetaldehyde by 68% (p¼ .0005) (Figure 3(B)).
Effect of slow-release L-cysteine on gastric juice
L-cysteine and MTCA
Ten minutes after intake, the L-cysteine level in gastric con-
tents was 83 ± 75 lmol/L. At 20min after intake, it reached
3333± 1941 lmol/L (Figure 4). With L-cysteine, the MTCA
levels were increased as compared to placebo (p< .0004)
reaching 22± 14 lmol/L at 10min and 60 ± 16 lmol/L at
20min (Figure 4). The L-cysteine peak of 7552± 2687lmol/L
was reached 40min after the intake of slow-release L-cysteine
capsules, whereas the peak MTCA level 196 ± 98 lmol/L
appeared first at 80min. Both compounds remained elevated
Figure 3. A. Effect of slow-release L-cysteine capsule formulation (Acetium) on
acetaldehyde concentrations in gastric contents of achlorhydric patients with
atrophic gastritis. p< .01, p< .001 (mean ± SEM; n¼ 7). B. Individual
exposures of the gastric mucosa to acetaldehyde during 240min after intragas-
tric instillation of ethanol (15 vol%, 0.3 g/kg bodyweight) with or without slow-
release L-cysteine capsule formulation (Acetium) (mean ± SEM; n¼ 7).p< .001. No error bars present in B.
Figure 2. Ethanol kinetics (vol%) in the stomach after intragastric instillation of
ethanol (15 vol%, 0.3 g/kg bodyweight) with placebo and slow-release L-cyst-
eine capsule formulation (Acetium) (mean ± SEM; n¼ 7).
Figure 4. A. Intragastric concentrations of L-cysteine and the non-toxic reaction
product 2-methyl-1,3-thiazolidine-4-carboxylic acid (MTCA) after covalent bind-
ing of L-cysteine to acetaldehyde in achlorhydric patients with atrophic gastritis
after the intake of slow-release L-cysteine capsules (Acetium 2 100mg) in
conjunction with intragastric instillation of alcohol (15 vol%, 0.3 g/kg body-
weight) (mean ± SEM; n¼ 7). B. Gastric exposure to acetaldehyde after ethanol
(15%vol) with and without L-cysteine in comparison with the presence of 2-
methyl-1,3-thiazolidine-4-carboxylic acid (MTCA) in gastric contents. #p< .05 in
comparison with ethanol plus placebo; p< .05 in comparison with ethanol
plus L-cysteine.
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for at least 160min (Figure 4(A)). In conjunction with this, the
intragastric MTCA AUC was 3-fold higher than acetaldehyde
AUC in the placebo-treated group (p¼ .0469) and 11-fold
higher than the corresponding acetaldehyde AUC (p¼ .0111)
when patients were treated with L-cysteine (Figure 4(B)). This
indicated a marked local turnover of ethanol to acetaldehyde
through gastric first-pass ethanol metabolism.
Discussion
According to Globocan 2012 statistics, stomach cancer is the
fifth most common malignancy worldwide with the third
highest mortality. The poor prognosis of gastric cancer
underlines the importance of preventive measures.[18,19] A
key to cancer prevention is the identification of the risk
groups and early detection of precancerous conditions.
Atrophic gastritis with hypochlorhydria is the most important
independent risk factor for gastric cancer.[19,20] The normal
acidic stomach contains few microbes, but in achlorhydric
patients, bacteria and yeast colonise the gastric contents.[21]
Some 35 years ago, it was proposed that gastric bacterial col-
onisation should lead to the intragastric conversion of nitrates
to nitrites, resulting in elaboration of potentially carcinogenic
N-nitroso compounds.[22] However, more recent cohort studies
failed to provide conclusive evidence.[23] On the other hand,
acetaldehyde is an underestimated risk factor for cancer devel-
opment in humans.[24,25] It causes chromosomal damage, with
sister-chromatid exchanges and chromosomal aberrations.[25,26]
It also reacts with 20-deoxyguanosine to form N2-ethyl-20-deoxy-
guanosine, leading to DNA adducts in animal models of ethanol
exposure and in white blood cells of humans.[27] To this end,
acetaldehyde inhibits DNA repair enzymes.[28]
Based on strong evidence derived from gene-epidemio-
logical and gene-biochemical studies on alcohol drinking
aldehyde dehydrogenase (ALDH)2-deficient individuals, acet-
aldehyde associated with the use of alcoholic beverages is
classified as carcinogenic (Group 1) to humans, now being
implicated as a risk factor for oral, pharyngeal and oesopha-
geal cancers.[25] The new classification applies to both acet-
aldehyde present in alcoholic beverages and that formed
endogenously from ethanol either by microbial or mucosal
oxidation processes.
A point mutation in ALDH2 gene resulting in deficient
activity of the main acetaldehyde metabolising enzyme
(ALDH2) is the most prevalent genetic health risk in the
world, passing in frequency that of familiar hypercholesterol-
emia. The prevalence of familial hypercholesterolemia is
1:500, but that of ALDH2 deficiency 1:13. The ALDH2 gene
point mutation took place in South China over 2000 years
ago. Its carrier frequency today is 600 million people of
East-Asian descent.[7,28] When drinking alcohol, those who
are ALDH2-deficient are exposed via saliva to 2- to 3-fold,
and via gastric juice to 5- to 6-fold higher acetaldehyde con-
centrations than those with active ALDH2 enzyme.[5,29,30]
Parallel to increased local acetaldehyde exposure, the risk of
ALDH2-deficient alcohol drinkers for oral, pharyngeal,
oesophageal and gastric cancer is many fold compared to
alcohol consumption in those with active ALDH2.[3,31,32]
The difference in cancer risk between ALDH2 deficiency and
active ALDH2 increases with increasing alcohol consumption.
Thus, ALDH2 deficiency provides a unique human cancer
model for acetaldehyde exposure, which proves the causal
relationship between acetaldehyde and upper digestive tract
cancers.
In this study, earlier findings on the powerful ability of
slow-release L-cysteine to eliminate acetaldehyde formed
through the gastric first-pass metabolism of ethanol in the
achlorhydric stomach secondary either to atrophic gastritis or
the use of PPIs, or H2-receptor blockers were confirmed.[5,16]
To this end, we found that orally administered slow-release
L-cysteine intragastrically forms the non-toxic MTCA com-
pound by binding to the reactive CHO-group of acetalde-
hyde. Peak MTCA concentrations of gastric juice were over
20-fold lower than MTCA levels found to be non-toxic to
Caco-2 cell lines in vitro.[33] MTCA is an endogenous product
that is detected in the blood after a moderate ethanol dose
(0.5 g/kg).[34] Furthermore, it has been shown that MTCA can
serve as a prodrug for L-cysteine and thus protect mice
against acetaminophen toxicity.[35]
Under the present study conditions, sufficiently high
L-cysteine levels for acetaldehyde neutralisation were achieved
in the gastric juice at 10–20min after L-cysteine (Acetium) cap-
sule intake. If taken earlier, gastric emptying may sweep away
some of the L-cysteine present in the stomach. L-cysteine and
MTCA were shown to remain in gastric contents for up to 3 h
after intake of slow-release L-cysteine formulation along with a
moderate amount of ethanol corresponding to about two
glasses of wine.
Ethanol itself is not carcinogenic, but acetaldehyde is. Due
to its reactive aldehyde group, acetaldehyde is a cytotoxic,
genotoxic and mutagenic compound.[24,25,36] Acetaldehyde
is carcinogenic to experimental animals and, in conjunction
with alcoholic beverages, strongly so to humans.[25] The
classification of acetaldehyde as a group 1 carcinogen con-
cerns both acetaldehyde present in alcoholic beverages and
as well that formed endogenously from ethanol.[25] After
alcohol intake, the highest concentrations of acetaldehyde in
man are found in saliva and achlorhydric stomach.[5,29,37]
This is due to the fact that parotid glands, oral microbes and
upper digestive tract mucosal cells are able to oxidise etha-
nol to acetaldehyde, but are not as capable of its detoxifica-
tion as liver.
The intragastric acetaldehyde concentrations found in our
study (peak level 85.6lmol/L) are considered to be muta-
genic both in vitro and in vivo.[37,38] Increasing concentra-
tions of acetaldehyde ranging from 25 to 500 lmol/L in the
presence of 20-deoxyguanosine or DNA and polyamines pro-
duce an exponential increase of mutagenic 1,N2-propano-
deoxyguanosine adducts.[37] Polyamine synthesis is tightly
related to cellular proliferation, with the highest levels being
found in rapidly dividing cells. This is characteristic for the
regenerating upper digestive tract mucosa.[39] Increased for-
mation of carcinogenic DNA adducts has also been demon-
strated in the gastric mucosa of ALDH2 gene knockout mice
treated with ethanol.[38] In human volunteers, low doses of
alcohol have been shown to produce a dose-dependent
increase in mutagenic acetaldehyde-DNA damage in the oral
cavity.[37] Corresponding doses of alcohol have been shown
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to result in 18.7–143.4 lmol/L acetaldehyde levels in sal-
iva,[17] which is similar to concentrations found in the stom-
ach of patients with atrophic gastritis in this and earlier
studies.[8,16]
A recent meta-analysis demonstrated that, compared with
non-drinkers, heavy drinking, but not moderate, is significantly
associated with gastric cancer.[1] Several other studies have
reported an increased incidence of gastric cancer among
ALDH2-deficient non-drinkers and among high consumers of
foodstuffs produced through fermentation where ethanol,
albeit at low concentrations, is elaborated.[40–43] The present
results showing acetaldehyde production in gastric juice at low
ethanol concentrations could explain the latter, and so far,
unrecognised association between ALDH2 deficiency and gas-
tric cancer. Many foodstuffs and ‘non-alcoholic’ beverages con-
sidered to be harmless may contain some ethanol and produce
elevated levels of endogenous acetaldehyde.[44,45] In this
study, the mean gastric ethanol concentrations from 40min to
120min throughout the study ranged from 3.0 to 0.1% which
was associated with mutagenic acetaldehyde concentrations
ranging from 28.5 to 85.6 lmol/L at 40min. Thus, in achlorhy-
dric subjects, even low ethanol levels in different foodstuffs
and beverages are associated with formation of mutagenic
concentrations of carcinogenic acetaldehyde via the gastric
first-pass metabolism of ethanol. This conclusion is in accord-
ance with our earlier findings in PPI-treated ALDH2-deficient
subjects.[5] The fact that ethanol and acetaldehyde intake via
widely used foodstuffs and beverages is not systematically
recorded causes an obvious, but yet unrecognised, confounder
and bias in cancer epidemiology of the upper digestive tract.
In the present study, with slow-release L-cysteine, the
peak acetaldehyde concentrations in gastric contents at
20min ranged from 2.8 to 20.2 lmol/L. Thus, the in vitro
mutagenic concentration of 25 lmol/L acetaldehyde was not
exceeded in any of the patients receiving slow-release L-cyst-
eine capsules.[37] The Acetium capsule used in these studies
is a CE-marked product that is registered in many countries
as a medical device (class IIa). This classification is based on
the nature of the active ingredient, L-cysteine, as a natural
amino acid and the mode of action of the formulation. L-
cysteine is a semi-essential sulphur-containing amino acid
that is widely used as a food additive. It is classified as
‘generally regarded as safe’ by both the European Food
Safety Administration (EFSA) and the US Food and Drug
Administration (FDA). Characteristically, slow-release L-cyst-
eine exerts its effect in the stomach, where acetaldehyde is
also formed. Acetium capsules contain L-cysteine, which is
bound to matrix granules with a matrix former. This causes
L-cysteine to be released at a sustained rate locally in the
stomach.[16] The use of a multi-particle system ensures that
the formulation spreads to as large a part of the stomach as
possible, even when the stomach contains solid or semi-solid
content. Granules can also be assumed to remain longer in
gastric mucosal folds, even in an upright position as gastric
contents are usually retained in the fundus portion of the
stomach. Aside from this, another interesting utility of the L-
cysteine family is with N-acetyl cysteine, which when added
to culture-based H. pylori eradication therapy has shown to
achieve higher eradication rates than standard culture-based
therapy in patients with a multi-resistant H. pylori
infection.[46]
The markedly increased AUC for MTCA as compared to
that for acetaldehyde in the presence of L-cysteine and etha-
nol confirmed substantial local oxidation of ethanol to acetal-
dehyde, i.e., gastric first-pass metabolism of ethanol
mediated by gastric mucosal cells and oral microbiota colo-
nising the acid-free stomach.[8,11,12] Atrophic gastritis
results in decreased mucosal alcohol dehydrogenase activity
and gastric first-pass metabolism of ethanol.[47] However,
the decreased mucosal ethanol metabolism in patients with
atrophic gastritis appears to be replaced by an enhanced
microbial acetaldehyde production. In this study, patients
were lying on their left side in order to enable sampling of
gastric juice. This procedure may have delayed gastric empty-
ing thereby significantly enhancing gastric first-pass metabol-
ism of ethanol and consequently also acetaldehyde,
L-cysteine and MTCA levels in gastric contents.[48]
An important limitation of our study is the fact that rela-
tively few subjects were used. This should reduce the power
of the study. However, using the patients as their own con-
trols increases the validity of the pharmacological principle of
L-cysteine capturing free acetaldehyde in the gastric lumen.
Since we obtained stable values with limited variability in our
acetaldehyde and MTCA assays reaching statistical signifi-
cance with clear differences already with seven individuals,
we decided to stop the recruitment at this point. Hence, the
pharmacological interaction between L-cysteine and acetal-
dehyde was shown.
In conclusion, acetaldehyde is the most common cumula-
tive human carcinogen.[49–51] It is present in most alcoholic
beverages and foodstuffs produced or preserved by fermen-
tation. Ethanol of alcoholic beverages is metabolised locally
in the upper digestive tract to acetaldehyde. Acetaldehyde is
widely used as an aroma agent and food additive. It is the
most abundant carcinogen of tobacco smoke, which, in part,
becomes dissolved in saliva and is in that manner distributed
to the mucosal surfaces of the upper digestive tract.
Generally accepted ALARA (As Low As Reasonably
Achievable) principles should be implemented to all Group 1
human carcinogens including acetaldehyde. Most important
is to avoid or decrease tobacco and alcohol consumption. In
well-defined risk groups, slow-release L-cysteine formulations
provide a novel and effective approach for the elimination of
carcinogenic acetaldehyde locally in the stomach where it is
formed. These risk groups include patients with achlorhydric
atrophic gastritis and regular users of gastric acid secretion
inhibitors (PPIs, H2-receptor blockers) as well as ALDH2-defi-
cient subjects, especially those with H. pylori infection or
chronic atrophic gastritis as diagnosed either by gastric
biopsy or by the GastroPanel blood test.[19] However, the
actual effectiveness of slow-release L-cysteine (Acetium) for-
mulation in cancer prevention remains to be evaluated in
prospective intervention studies.
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